HYPOADIPONECTINEMIA AND DYSLIPIDEMIA IN RELATION TO GLYCEMIC STATUS IN TYPE 2 DIABETES AND CORONARY HEART DISEASE
Article Sidebar
Main Article Content
Abstract
OBJECTIVE: to study the relationship of adiponectin level with lipid
profile and glycemic control in type 2 diabetic subjects with and without
coronary heart disease (CHD).
METHODOLOGY: This cross-sectional/ analytical study consisted of
three groups. Group A consisted of 60 healthy subjects, group B consisted of 60 type 2 diabetic subjects and group C consisted of 60 type
2 diabetic subjects with coronary heart disease. The study participants
were analyzed for serum adiponectin level, triglycerides (TG), total
cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low
density lipoprotein cholesterol (LDL-C), very low density lipoprotein
cholesterol (VLDL-C), fasting blood glucose (FBG) and glycosylated
hemoglobin (HbA1c).
RESULTS: Significantly high adiponectin level was observed in female
subjects as compared to male subjects. Type 2 diabetic subjects with
and without coronary heart disease presented with significantly higher
FBG, HbA1c, TC and TG (p value <0.05) and significantly lower levels
of serum adiponectin and HDL-C (p value <0.001). Adiponectin level
showed significant positive association with HDL-C in control group
(female: r 0.988; p=<0.01, male: r 0.948; p=<0.01), type 2 diabetic
group (female: r 0.908; p=<0.01, male: r 0.860; p=<0.01) and type 2
diabetic group having coronary heart disease (female: 0.775; p=<0.01,
male: 0.650; p=<0.01). Significant (p value <0.01) negative association
of adiponectin was observed with TG, FBG and HbA1c in type 2 diabetic
subjects with and without coronary heart disease.
CONCLUSION: Hypoadiponectinemia in type 2 diabetic subjects with
and without coronary heart disease is related with un-controlled glycemic
status and dyslipidemia.
Article Details
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online
(e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
References:
Anietabasi SO, Chinyere AO, Anousta
CN, Edmund RE, John UE, Anthony JU.
Adiponectin and cardiovascular risk factors
in relation with glycemic control in
type 2 diabetics. Int J Res Med Sci 2013;
(4): 563-70.
Mahler RJ, Adler ML. Type 2 diabetes mellitus:
Update on diagnosis, pathophysiology,
and treatment. J Clin Endocrinol Metab
; 84(4): 1165-71.
Efimov A, Sokolova L, Sokolov M. Diabetes
and coronary heart disease. Diabetol
Croat 2001; 30(4): 115-20.
Wild S, Roglic G, Green A, Sicree R, King
H. Global prevalence of diabetes. Estimates
for the year 2000 and projections
for 2030. Diabetes Care 2004; 27(5):
-53.
Robinson K, Prins J, Venkatesh B. Clinical
review: Adiponectin biology and its role in
inflammation and critical illness. Crit Care
; 15(2): 221-9.
Wells JC. Sexual dimorphism of body
composition. Best Pract Res Clin 2007;
: 415-30.
Ibrahim MM. Subcutaneous and visceral
adipose tissue: structural and functional
differences. Obes Rev 2010; 11: 11-8.
Ramirez ML, Garcia MAM, Nieto RM, Duran
EF, Insenser M, Alpanes M et al. Sexual
dimorphism in adipose tissue function as
evidenced by circulating adipokine secretions
in the fasting state and after an oral
glucose challenge. Human Reproduction
; 28(7): 1908-18.
Tsao TS1, Tomas E, Murrey HE, Hug C,
Lee DH, Ruderman NB, Heuser JE, Lodish
HF Role of disulfide bonds in Acrp30/
adiponectin structure and signaling specificity.
Different oligomers activate different
signal transduction pathways. J Biol Chem
Dec 12;278(50):50810-7.
Kadowaki T, Yamuchi T. Adiponectin and
adiponectin receptors. Endocr Rev 2005;
(3): 439-51.
Takemura Y, Walsh K, Ouchi N. Adiponectin
and cardiovascular inflammatory
responses. Curr Atheroscler Rep 2007;
(3): 238-43.
Geloneze B, Pereira JA, Pareja JC, Lima
MM, Lazarin MA, Souza IC, et al. Overcoming
metabolic syndrome in severe
obesity: Adiponectin as a marker of insulin
sensitivity and HDLcholesterol improvements
after gastric bypass. Arq Bras
Endocrinol Metabol 2009; 53: 293300.
Maruyama C, Ishibashi R, Araki R, Koike S,
Hirose H, Maruyama T. HMW adiponectin
associates with triglyceride concentrations
in type 1 diabetic patients. J Atheroscler
Thromb 2009; 16: 20716.
Friedwald WT, Levy PI, Fredrickson DS.
Estimation of concentration of low density
lipoprotein cholesterol in plasma, without
use of the preparative centrifuge. Clin
Chem 1972; 18(6): 449-502.
Delong DM, Delong ER, Wood PD, Lippet
K, Rifkind BM. A comparison of methods
for the estimation of plasma low and very
low density lipoprotein cholesterol. J Am
Med Assoc 1986; 256(17): 2372-7.
Lincoff AM, Wolski K, Nicholls SJ, Nissen
SE. Pioglitazone and risk of cardiovascular
events in patients with type 2 diabetes
mellitus: a meta-analysis of randomized
trials. J Am Med Assoc 2007; 298: 1180-8.
Tomas E, Tsao TS, Saha AK, Murrey HE,
Zhang Cc, Itani Si, Lodish HF, Ruderman
NB. Enhanced muscle fat oxidation and
glucose transport by Acrp30 globular
domain: acetyl CoA carboxylase inhibition
and AMP-activated protein kinase
activation. Proc Nat Acad Sci USA 2002;
(25): 16309-13.
Hopkins TA, Ouchi N, Shibata R, Walsh K.
Adiponectin actions in the cardiovascular
system. Cardiovasc Res 2007; 74(1): 11-8.
Bansal S, Buring JE, Rifai N, Mora S, Sacks
FM, Ridker PM. Fasting compared with
non-fasting triglycerides and risk of cardiovascular
events in women. J Am Med
Assoc 2007; 298(3): 299-308.
Lewis GF, Rader DJ. New insights into
the regulation of HDL metabolism and
reverse cholesterol transport. Circ Res
; 96(12): 1221-32.
Plant S, Shand B, Elder P, Scott R. Adiponectin
attenuates endothelial dysfunction
induced by oxidised low-density
lipoproteins. Diab Vasc Dis Res 2008;
(2): 120-8.
Cote M, Mauriege P, Bergeron J, Almeras
N, Tremblay A, Lemieux I, et al. Adiponectin
in visceral obesity: impact on glucose
tolerance and plasma lipoprotein and lipid
levels in men. J Clin Endocrinol Metab
; 90:14349.
Qiao I, Zou C, Van Der Westhuyzen
DR, Shao J. Adiponectin reduces plasma
triglyceride by increasing VLDL triglyceride
catabolism. Diabetes 2008; 57(7):
-33.
Nayak SB, Maharaj N, Fatt LaL. Association
between altered lipid profile, body
mass index, low plasma adiponectin and
varied blood pressure in Trinidad type 2
diabetic and non-diabetic subjects. J Med
Sci 2012; 65(9): 214-21.
Yamamoto S, Matsushita Y, Nakagawa T,
Hayashi T, Noda M, Mizoue T. Circulating
adiponectin levels and risk of type 2
diabetes in the Japanese. Nutr Diabetes.
Aug; 4(8): e130. doi: 10.1038/
nutd.2014.27
Matsushita Y, Nakagawa T, Yamamota S,
Kato T, Ouchi T et al. Adiponectin and
visceral fat associate with cardiovascular
risk factors. Obesity 2014; 21: 287-91.
Saely CH, Riseh L, Hoefle G, Rein P,
Muendlein A, Marte T, et al. Low serum
adiponectin is independently associated
with both the metabolic syndrome and
angiographically determined coronary
atherosclerosis. Clin Chim Acta 2007(1-2);
: 97-102.
Luo M, Oza-Frank R, Narayan KMV,
Gokulakrishnan K, Mohan V. Serum total
adiponectin is associated with impaired
glucose tolerance in Asian Indian females
but not in males. J Diab Sci Tech 2010;
(3): 645-50.
Rasul S, Iihan A, M. H. Reiter, Baumgartner-
Parzer S, Kautzky-willer A. Relations
of adiponectin to levels of metabolic parameters
and sexual hormones in elderly
type 2 diabetic patients. Gender Medicine
; 8(2): 93-102.
Katsiki N, Mikhailidis DP, Gotzamani-
Psarrakou A, Didangelos TP, Yovos
JG, Karamitsos DT. Effects of improving
glycemic control with insulin on leptin,
adiponectin, ghrelin and neuropeptide
Y levels in patients with type 2 diabetes
mellitus: a pilot study. Open Cardiovasc
Med J 2011; 5(6): 136-47.
Kawamoto R, Tabara Y, Kohara K, Miki T,
Kusunoki T, Takayama S, Abe M, Katoh T,
Ohtsuka N. Relationships between lipid
profiles and metabolic syndrome, insulin
resistance and serum high molecular adiponectin
in Japanese community-dwelling
adults. Lipids Health Dis 2011; 10(79): 1-7.
Tabak AG, Brunner EJ, Miller MA, Karanam
S, McTernan PG, Cappuccino FP, et al. Low
serum adiponectin predicts 10-year risk of
type 2 diabetes and HbA1c independently
of obesity, lipids and inflammation-Whitehall
II study. Horm Met Res 2009; 41(8):
-9.
Snijder MB, Heine RJ, Seidell JC, Bouter
LM, Stehouwer CDA, Nijpels G, et al.
Associations of adiponectin levels with
incident impaired glucose metabolism and
type 2 diabetes in older men and women.
Diabetes Care 2006; 29(11): 2498-503.
Eynatten MV, Hamann A, Twardella D,
Nawroth PP, Brenner H, Rothenbacher D.
Relationship of adiponectin with markers
of systemic inflammation, atherogenic
dyslipidemia, and heart failure in patients
with coronary heart disease. Clin Chem
; 52(5): 853-9.
Kistorp C, Faber J, Galatius S, Gustafssen
F, Frystyk J, Flyvberg A, et al. Plasma adiponectin,
body mass index, and mortality
in patients with chronic heart failure. Circulation
; 112: 1756-62.
Laughlin GA, Barrett-Connor E, May S,
Langenberg C. Association of adiponectin
with coronary heart disease and mortality:
the Rancho Bernado study. Am J Epidemiol
; 165: 164-74.